Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines

By Collins D.   Crown J.   O’Donovan N.   Devery A.   O’Sullivan F.   O’Driscoll L.   Clynes M.   O’Connor R.  

Investigational New Drugs, Vol. 28, Iss. 4, 2010-08 ,pp. : 433-444

Springer Publishing Company

Access to resources Recommend Favorite

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non–small cell lung cancer during treatment with erlotinib

By  

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3896-3901

Blackwell Publishing

Access to resources Recommend Favorite

Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer

By  

Current Drug Targets, Vol. 11, Iss. 7, 2010-07 ,pp. : 851-864

Bentham Science Publishers

Access to resources Recommend Favorite

Putting the Brakes on Cancer: Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

By  

Pharmaceutical Innovation, Vol. 12, Iss. 1, 2002-12 ,pp. : 12-15

Adis International

Access to resources Recommend Favorite

Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients

By Li Jing   Brahmer Julie   Messersmith Wells   Hidalgo Manuel   Baker Sharyn  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite